ArticleThe Lancet regional health. Europe2023

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.

Júlia Corominas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.